We Think Some Shareholders May Hesitate To Increase SMS Pharmaceuticals Limited's (NSE:SMSPHARMA) CEO Compensation

Key Insights

• SMS Pharmaceuticals' Annual General Meeting to take place on 29th of September
• Salary of ₹30.0m is part of CEO Ramesh Potluri's total remuneration
• The overall pay is 68% above the industry average
• Over the past three years, SMS Pharmaceuticals' EPS grew by 37% and over the past three years, the total shareholder return was 235%

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

CEO Ramesh Potluri has done a decent job of delivering relatively good performance at SMS Pharmaceuticals Limited (NSE:SMSPHARMA) recently. In light of this performance, CEO compensation will probably not be the main focus for shareholders as they go into the AGM on 29th of September. However, some shareholders may still want to keep CEO compensation within reason.

View our latest analysis for SMS Pharmaceuticals

Comparing SMS Pharmaceuticals Limited's CEO Compensation With The Industry

At the time of writing, our data shows that SMS Pharmaceuticals Limited has a market capitalization of ₹27b, and reported total annual CEO compensation of ₹52m for the year to March 2025. That's a notable increase of 41% on last year. We note that the salary of ₹30.0m makes up a sizeable portion of the total compensation received by the CEO.

For comparison, other companies in the Indian Pharmaceuticals industry with market capitalizations ranging between ₹18b and ₹71b had a median total CEO compensation of ₹31m. Hence, we can conclude that Ramesh Potluri is remunerated higher than the industry median. Moreover, Ramesh Potluri also holds ₹5.5b worth of SMS Pharmaceuticals stock directly under their own name, which reveals to us that they have a significant personal stake in the company.

Speaking on an industry level, nearly 99% of total compensation represents salary, while the remainder of 0.79361173% is other remuneration. SMS Pharmaceuticals pays a modest slice of remuneration through salary, as compared to the broader industry. If salary is the major component in total compensation, it suggests that the CEO receives a higher fixed proportion of the total compensation, regardless of performance.

SMS Pharmaceuticals Limited's Growth

SMS Pharmaceuticals Limited has seen its earnings per share (EPS) increase by 37% a year over the past three years. It achieved revenue growth of 10% over the last year.

Overall this is a positive result for shareholders, showing that the company has improved in recent years. It's a real positive to see this sort of revenue growth in a single year. That suggests a healthy and growing business. Although we don't have analyst forecasts, you might want to assess this data-rich visualization of earnings, revenue and cash flow.

Has SMS Pharmaceuticals Limited Been A Good Investment?

We think that the total shareholder return of 235%, over three years, would leave most SMS Pharmaceuticals Limited shareholders smiling. As a result, some may believe the CEO should be paid more than is normal for companies of similar size.

To Conclude...

The company's decent performance might have made most shareholders happy, possibly making CEO remuneration the least of the concerns to be discussed in the upcoming AGM. However, any decision to raise CEO pay might be met with some objections from the shareholders given that the CEO is already paid higher than the industry average.

While CEO pay is an important factor to be aware of, there are other areas that investors should be mindful of as well. We did our research and spotted 1 warning sign for SMS Pharmaceuticals that investors should look into moving forward.

Of course, you might find a fantastic investment by looking at a different set of stocks. So take a peek at this free list of interesting companies.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.